Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Abuse and Addiction: Pharmacological Phenomena01:15

Drug Abuse and Addiction: Pharmacological Phenomena

447
Drug dependence, abuse, and addiction are complex phenomena that can precipitate various abnormal states. Physical dependence refers to a state of pharmacological adaptation to a drug. This adaptation often results in tolerance—a reduced response to the drug after repeated administrations. When the drug use is abruptly stopped, withdrawal symptoms occur due to the body's need to readjust from the pharmacologically induced imbalance. However, tolerance and withdrawal symptoms do not...
447
CNS Depressants: Alcohol and Nicotine01:27

CNS Depressants: Alcohol and Nicotine

179
Ethanol, a clear colorless alcohol, has been consumed by humans for millennia, but its effects on the body are far from benign. At lower doses, it induces decreased inhibitions and loquaciousness, leading to its social appeal. However, it can cause severe consequences at higher doses, such as coma and respiratory depression, due to its zero-order elimination kinetics. Chronic ethanol abuse wreaks havoc on multiple organ systems, particularly the CNS and the liver. Abrupt cessation of ethanol...
179
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists01:30

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

106
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
106
Substance Use Disorders Affecting Sleep01:24

Substance Use Disorders Affecting Sleep

161
Substance use disorders involve a pattern of using drugs more extensively than intended and continuing use despite harmful consequences. This includes legal substances like alcohol and nicotine, as well as illegal drugs. These disorders often involve both physical and psychological dependence, reflecting compulsive use of substances that significantly alter thoughts, feelings, and behaviors, contributing to a major public health issue.
Understanding the concepts of physical dependence,...
161
CNS Stimulants: Cocaine, Amphetamines and Cannabinoids01:24

CNS Stimulants: Cocaine, Amphetamines and Cannabinoids

167
CNS stimulants, such as cocaine, amphetamines, and cannabinoids, have varying structures and mechanisms of action that lead to different therapeutic effects and side effects. Cocaine, with its molecular formula C17H21NO4, is a tropane alkaloid and a tertiary amino compound. It has two chemical forms: the hydrochloride salt and the "freebase." The former is in powder form, while the latter involves removing the hydrochloride salt to create a form that can be smoked. Cocaine exerts its...
167

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Opioid Agonist Treatment Use Among First Nation Peoples in Ontario, Canada: A Repeated Cross-sectional Study of Prevalence Trends From 2013 to 2023.

Journal of addiction medicine·2026
Same author

The Comparative Efficacy of Noninvasive Brain Stimulation for Suicidal Ideation: A Network Meta-Analysis.

The American journal of psychiatry·2026
Same author

Safer opioid supply initiation among First Nations Peoples in Ontario, Canada, 2019 to 2023.

The International journal on drug policy·2026
Same author

Racial discrimination in healthcare and public settings as a predictor of suicidal ideation onset among U.S. Adults with baseline depressive symptoms.

Social psychiatry and psychiatric epidemiology·2026
Same author

The Effects of Extended Cannabis Abstinence in Comorbid Posttraumatic Stress Disorder and Cannabis Use Disorder.

The Journal of clinical psychiatry·2026
Same author

Polygenic risk moderation of stressful life events in alcohol use disorder severity.

BMC psychiatry·2026

Related Experiment Video

Updated: Jun 12, 2025

A Protocol for Measuring Cue Reactivity in a Rat Model of Cocaine Use Disorder
07:51

A Protocol for Measuring Cue Reactivity in a Rat Model of Cocaine Use Disorder

Published on: June 18, 2018

10.5K

Cognitive Dysfunction in the Addictions (CDiA): protocol for a neuron-to-neighbourhood collaborative research

Yuliya S Nikolova1,2,3, Anthony C Ruocco1,2,3,4, Daniel Felsky1,2,5

  • 1Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, ON, Canada.

Frontiers in Psychiatry
|June 4, 2025
PubMed
Summary
This summary is machine-generated.

Cognitive dysfunction, specifically executive functions (EFs), plays a key role in substance use disorders (SUDs). Understanding EFs

Keywords:
addictionalcohol use disordercognitionexecutive functionpreclinicalsubstance use disordertranslational

More Related Videos

Disruption of Frontal Lobe Neural Synchrony During Cognitive Control by Alcohol Intoxication
09:26

Disruption of Frontal Lobe Neural Synchrony During Cognitive Control by Alcohol Intoxication

Published on: February 6, 2019

18.7K
Chronic Intermittent Ethanol Vapor Exposure Paired with Two-Bottle Choice to Model Alcohol Use Disorder
05:12

Chronic Intermittent Ethanol Vapor Exposure Paired with Two-Bottle Choice to Model Alcohol Use Disorder

Published on: June 23, 2023

878

Related Experiment Videos

Last Updated: Jun 12, 2025

A Protocol for Measuring Cue Reactivity in a Rat Model of Cocaine Use Disorder
07:51

A Protocol for Measuring Cue Reactivity in a Rat Model of Cocaine Use Disorder

Published on: June 18, 2018

10.5K
Disruption of Frontal Lobe Neural Synchrony During Cognitive Control by Alcohol Intoxication
09:26

Disruption of Frontal Lobe Neural Synchrony During Cognitive Control by Alcohol Intoxication

Published on: February 6, 2019

18.7K
Chronic Intermittent Ethanol Vapor Exposure Paired with Two-Bottle Choice to Model Alcohol Use Disorder
05:12

Chronic Intermittent Ethanol Vapor Exposure Paired with Two-Bottle Choice to Model Alcohol Use Disorder

Published on: June 23, 2023

878

Area of Science:

  • Neuroscience
  • Psychiatry
  • Public Health

Background:

  • Substance use disorders (SUDs) are a significant global health challenge.
  • Executive functions (EFs) are implicated in addiction mechanisms, but their role in SUDs requires further elucidation.
  • Existing research has gaps in understanding EFs' links to neural circuits, biomarkers, disorder heterogeneity, and functional outcomes.

Purpose of the Study:

  • To introduce the Cognitive Dysfunction in the Addictions (CDiA) program, an integrative research initiative.
  • To investigate the crucial role of EFs in functional outcomes for individuals with SUDs.
  • To fill knowledge gaps and drive discoveries for enhanced SUD treatments.

Main Methods:

  • An interdisciplinary program involving seven projects with a target sample of 400 adults (aged 18-60) undergoing SUD treatment.
  • Longitudinal follow-up over one year to assess associations between SUDs, EFs (inhibition, working memory, set-shifting), neural circuits, biomarkers, and functional outcomes.
  • Includes clinical trials (repetitive transcranial magnetic stimulation), preclinical studies, healthcare utilization analysis, qualitative research, and advanced data modeling (clustering, deep learning).

Main Results:

  • Projects 1-3 examine relationships between SUD symptoms, brain circuits, blood biomarkers, EFs, and functional outcomes (disability, quality of life).
  • Projects 4-5 evaluate interventions impacting EFs in SUDs.
  • Project 6 links EFs to healthcare use and treatment engagement barriers.
  • Project 7 integrates multi-modal data to identify patient subtypes using advanced computational methods.

Conclusions:

  • The CDiA Program aims to integrate diverse scientific domains to understand EFs' link to SUD severity and recovery.
  • Findings will facilitate novel discoveries to improve treatments and health outcomes for individuals with SUDs.
  • This research supports a holistic, biopsychosocial approach to addressing cognitive aspects of addiction.